AKYNZEO® recommended by NCCN and ASCO
AKYNZEO is a recommended option in the NCCN antiemesis guidelines and the ASCO antiemesis guidelines1,2
- NCCN recommends that patients receiving highly emetogenic chemotherapy (including anthracycline plus cyclophosphamide) and moderately emetogenic chemotherapy receive AKYNZEO in combination with dexamethasone1
- ASCO recommends that all patients who receive highly emetogenic chemotherapy regimens should be offered the oral combination of netupitant and palonosetron plus dexamethasone as an additional treatment option2
NCCN=National Comprehensive Cancer Network.
ASCO=American Society of Clinical Oncology.
References: 1. The NCCN Clinical Practice Guidelines in Oncology®. Antiemesis (Version 2.2015). © 2015 National Comprehensive Cancer Network, Inc. http://www.nccn.org/. Accessed January 8, 2016.
2. Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. ePub 2015 Nov 2. DOI: 10.1200/JCO.2015.64.3635.